Taysha Gene Therapies SG&A Expenses 2020-2024 | TSHA
Taysha Gene Therapies sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Taysha Gene Therapies Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$30 |
| 2022 |
$37 |
| 2021 |
$41 |
| 2020 |
$11 |
| 2019 |
$ |
Taysha Gene Therapies Quarterly SG&A Expenses
(Millions of US $) |
| 2024-06-30 |
$7 |
| 2024-03-31 |
$7 |
| 2023-12-31 |
$7 |
| 2023-09-30 |
$9 |
| 2023-06-30 |
$6 |
| 2023-03-31 |
$9 |
| 2022-12-31 |
$7 |
| 2022-09-30 |
$9 |
| 2022-06-30 |
$10 |
| 2022-03-31 |
$11 |
| 2021-12-31 |
$12 |
| 2021-09-30 |
$11 |
| 2021-06-30 |
$10 |
| 2021-03-31 |
$8 |
| 2020-12-31 |
$6 |
| 2020-09-30 |
$4 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.490B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
